• Incyte disclosed pivotal Phase 3 frontMIND results, already presented at EHA 2026 and recently published.
• The tafasitamab-lenalidomide add-on to R-CHOP improved disease control in first-line high-risk DLBCL or HGBL versus standard R-CHOP.
• Findings supported a favorable trend in survival, though the survival readout remained inconclusive at this analysis.
• Safety was broadly consistent with expectations, with more severe side effects but similar treatment discontinuation rates versus R-CHOP.
• Data set up global regulatory filings for the regimen in previously untreated DLBCL or HGBL.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260613831839) on June 13, 2026, and is solely responsible for the information contained therein.